Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3CNS 2NET 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Neural crest tumor 1

Interventions

lutetium Lu 177 dotatate 43-Iodobenzylguanidine 3gallium Ga 68 dotatate 2Temozolomide 2Capecitabine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Immunotherapy 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Drug Therapy 1Cyclophosphamide 1Cryosurgery 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × 3-fluorobenzylguanidine × NET × Clear all
NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Peking Union Medical College Hospital

Phase EARLY_PHASE1 Recruiting
150 enrolled
CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡